Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Core Insights - Structure Therapeutics Inc. is set to release topline data from its ACCESS clinical program for aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist aimed at treating obesity, on December 8, 2025 [1] - A conference call and webcast will be held by management to discuss the data at 8:30 a.m. ET on the same day [1] Company Overview - Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule treatments for chronic metabolic conditions, particularly obesity [3] - The company utilizes a next-generation structure-based drug discovery platform to create a robust pipeline targeting GPCR, featuring multiple proprietary clinical-stage oral small molecule compounds [3] - The aim is to overcome the scalability limitations of traditional biologic and peptide therapies, making treatments more accessible to individuals with obesity globally [3]